高分化/去分化脂肪肉瘤的疾病特征及免疫相关治疗的研究进展

doi:10.11904/j.issn.1002-3070.2024.04.011

Abstract

Abstract: Liposarcoma is a common soft tissue malignant tumor with multiple histological types,among which well-differentiated liposarcoma and dedifferentiated liposarcoma are the largest subgroups of liposarcoma. After conventional treatment,the 5-year survival rate of patients with dedifferentiated liposarcoma has not been significantly improved. In recent years,immunotherapy has shown significant efficacy in tumors such as melanoma and lung cancer,and has been widely studied in well-differentiated liposarcoma and dedifferentiated liposarcoma. This article summarizes the clinical and genetic features of well-differentiated liposarcoma and dedifferentiated liposarcoma,conventional treatment methods,and the application of immunotherapy in liposarcoma,including immune checkpoint inhibitors,adoptive cell therapy,oncolytic viruses,cancer vaccines,and immunotherapy combined with other treatment options. Integrating immune-related treatment options for liposarcoma is an urgent problem to be solved,and it also provides broad ideas for clinical work to understand liposarcoma and new management and treatment strategies.

Key words: Well-differentiated/dedifferentiated liposarcoma, Disease characteristics, Immunotherapy

CLC Number:

XU Yaojie, CHANG Yihang, MO Piman, BAO Junjie. Research progress on disease characteristics and immune-related treatment of well-differentiated/dedifferentiated liposarcoma[J]. Journal of Practical Oncology, 2024, 38(4): 278-282.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2024.04.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2024/V38/I4/278

References

1 Sbaraglia M,Bellan E,Dei Tos AP.The 2020 WHO classification of soft tissue tumours:news and perspectives[J].Pathologica,2021,113(2):70-84.
2 Thway K.Well-differentiated liposarcoma and dedifferentiated liposarcoma:an updated review[J].Semin Diagn Pathol,2019,36(2):112-121.
3 Thway K,Jones RL,Noujaim J,et al.Dedifferentiated liposarcoma:updates on morphology,genetics,and therapeutic strategies[J].Adv Anat Pathol,2016,23(1):30-40.
4 Zhou MY,Bui NQ,Charville GW,et al.Treatment of de-differentiated liposarcoma in the era of immunotherapy[J].Int J Mol Sci,2023,24(11):9571.
5 Kim YJ,Yu DB,Kim M,et al.Adipogenesis induces growth inhibition of dedifferentiated liposarcoma[J].Cancer Sci,2019,110(8):2676-2683.
6 Resag A,Toffanin G,Benešová I,et al.The immune contexture of liposarcoma and its clinical implications[J].Cancers,2022,14(19):4578.
7 Dang TN,Tiongco RP,Brown LM,et al.Expression of the preadipocyte marker ZFP423 is dysregulated between well-differentiated and dedifferentiated liposarcoma[J].BMC Cancer,2022,22(1):300.
8 Lee A TJ,Thway K,Huang PH,et al.Clinical and molecular spectrum of liposarcoma[J].J Clin Oncol,2018,36(2):151-159.
9 Zhou S,Zhang C,Zhang Z,et al.A novel HMGA2:KITLG fusion in a dedifferentiated liposarcoma with amplification of MDM2 and HMGA2[J].Genes Chromosomes Cancer,2023,63:e23200.
10 Lu J,Wood D,Ingley E,et al.Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma[J].Molecular Biology Reports,2021,48(4):3637-3647.
11 Wang Y,Hu L,Wang J,et al.HMGA2 promotes intestinal tumorigenesis by facilitating MDM2-mediated ubiquitination and degradation of P53[J].J Pathol,2018,246(4):508-518.
12 Denis C J,Deiteren K,Hendriks D,et al.Carboxypeptidase M in apoptosis,adipogenesis and cancer[J].Clin Chim Acta,2013,415:306-316.
13 Mashima E,Sawada Y,Nakamura M.Recent advancement in atypical lipomatous tumor research[J].Int J Mol Sci,2021,22(3):994.
14 Suarez-Kelly LP,Baldi GG,Gronchi A.Pharmacotherapy for Liposarcoma:current state of the art and emerging systemic treatments[J].Expert Opin Pharmacother,2019,20(12):1503-1515.
15 von Mehren M,Kane JM,Agulnik M,et al.Soft tissue sarcoma,version 2.2022,NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2022,20(7):815-833.
16 Tanaka K,Ozaki T.Adjuvant and neoadjuvant chemotherapy for soft tissue sarcomas:jcog bone and soft tissue tumor study group[J].Jpn J Clin Oncol,2021,51(2):180-184.
17 Seddon B,Strauss SJ,Whelan J,et al.Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas(GeDDiS):a randomised controlled phase 3 trial[J].Lancet Oncol,2017,18(10):1397-1410.
18 Schöffski P,Chawla S,Maki RG,et al.Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma:a randomised,open-label,multicentre,phase 3 trial[J].Lancet,2016,387(10028):1629-1637.
19 Cassinelli G,Pasquali S,Lanzi C.Beyond targeting amplified MDM2and CDK4 in well differentiated and dedifferentiated liposarcomas:from promise and clinical applications towards identification of progression drivers[J].Frontiers in Oncology,2022,12:965261.
20 Tan DS,Bedard PL,Kuruvilla J,et al.Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy[J].Cancer Discov,2014,4(5):527-537.
21 Gounder MM,Razak AA,Somaiah N,et al.Selinexor in advanced,metastatic dedifferentiated liposarcoma:a multinational,randomized,double-blind,placebo-controlled trial[J].J Clin Oncol,2022,40(22):2479-2490.
22 Abdul Razak AR,Bauer S,Suarez C,et al.Co-targeting of MDM2 and CDK4/6 with siremadlin and ribociclib for the treatment of patients with well-differentiated or dedifferentiated liposarcoma:results from a proof-of-concept,phase Ib study[J].Clin Cancer Res,2022,28(6):1087-1097.
23 Song Z,Lu L,Gao Z,et al.Immunotherapy for liposarcoma:emerging opportunities and challenges[J].Future Oncol,2022,18(30):3449-3461.
24 Italiano A,Bellera C,D′Angelo S.PD1/PD-L1 targeting in advanced soft-tissue sarcomas:a pooled analysis of phase II trials[J].J Hematol Oncol,2020,13(1):55.
25 Somaiah N,Conley AP,Parra ER,et al.Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas:a single-withcentre phase 2 trial[J].Lancet Oncol,2022,23(9):1156-1166.
26 D′Angelo SP,Mahoney MR,Van Tine BA,et al.Nivolumab or without ipilimumab treatment for metastatic sarcoma(Alliance A091401):two open-label,non-comparative,randomised,phase 2 trials[J].Lancet Oncol,2018,19(3):416-426.
27 Toulmonde M,Brahmi M,Giraud A,et al.Trabectedin ius durvalumab in patients with advanced pretreated soft tissue sarcoma and ovarian carcinoma(TRAMUNE):an open-label,multicenter phase Ib study[J].Clin Cancer Res,2022,28(9):1765-1772.
28 Snow H,Mitchell C,Hendry S,et al.Characterising the immune microenvironment in liposarcoma,its impact on prognosis and the impact of radiotherapy[J].J Surg Oncol,2021,123(1):117-126.
29 You Y,Guo X,Zhuang R,et al.Activity of PD-1 inhibitor combined with anti-angiogenic therapy in advanced sarcoma:a single-center retrospective analysis[J].Front Mol Biosci,2021,8:747650.
30 Mullinax JE,Hall M,Beatty M,et al.Expanded tumor-infiltrating lymphocytes from soft tissue sarcoma have tumor-specific function[J].J Immunother,2021,44(2):63-70.
31 Ahmed N,Brawley VS,Hegde M,et al.Human epidermal growth factor receptor 2(HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma[J].J Clin Oncol,2015,33(15):1688-1696.
32 Kaufman HL,Kohlhapp FJ,Zloza A.Oncolytic viruses:a new class of immunotherapy drugs[J].Nat Rev Drug Discov,2016,15(9):660.
33 Kelly CM,Antonescu CR,Bowler T,et al.Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab:a phase 2 clinical trial[J].JAMA Oncol,2020,6(3):402-408.
34 Smith H G,Mansfield D,Roulstone V,et al.PD-1 blockade following isolated limb perfusion with vaccinia virus prevents local and distant relapse of soft-tissue sarcoma[J].Clin Cancer Res,2019,25(11):3443-3454.
35 Constantino J,Gomes C,Falcão A,et al.Dendritic cell-based immunotherapy:a basic review and recent advances[J].Immunol Res,2017,65(4):798-810.
36 Pollack SM The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients[J].Expert Rev Vaccines,2018,17(2):107-114.
37 Somaiah N,Chawla SP,Block MS,et al.A phase 1b study evaluating the safety,tolerability,and immunogenicity of CMB305,a lentiviral-based prime-boost vaccine regimen,in patients with locally advanced,relapsed,or metastatic cancer expressing NY-ESO-1[J].Oncoimmunology,2020,9(1):1847846.

[1]	ZHAO Lu, ZHANG Zhengfeng, WANG Dazhen, YANG Liu, LIU Ze, LOU Changjie. The current application status of immunotherapy in solid tumors [J]. Journal of Practical Oncology, 2024, 38(1): 55-61.
[2]	CHU Sitong, XU Qingyong. Research progress on immunotherapy resistance mechanisms of triple-negative breast cancer [J]. Journal of Practical Oncology, 2023, 37(5): 449-453.
[3]	LU Hongnan, XIA Bingshu, QIAO Kun, ZHANG Shiyuan, HUANG Yuanxi, LU Xiangshi. Relationship between GAS1,immunotherapy and drug sensitivity in breast cancer [J]. Journal of Practical Oncology, 2023, 37(4): 351-359.
[4]	LI Fucheng, JIA Siyuan, BA Yuling, LUO Danli, XIAO Min. Research progress of immune checkpoint inhibitors in neoadjuvant therapy of early breast cancer [J]. Journal of Practical Oncology, 2023, 37(4): 367-371.
[5]	LI Juan, LIU Jiaren. The current research status and progress of immunotherapy for gastric cancer [J]. Journal of Practical Oncology, 2023, 37(4): 372-376.
[6]	LI Luqiao, ZOU Zhengyun. Current status of advanced research on immunotherapy for malignant melanoma [J]. Journal of Practical Oncology, 2023, 37(2): 144-148.
[7]	WANG Jiabei, ZHANG Yunguang, LIU Lianxin. Clinical efficacy and safety analysis of immunotherapy combined with molecularly targeted drugs in the treatment of advanced hepatocellular carcinoma:A single-arm retrospective study [J]. Journal of Practical Oncology, 2022, 36(6): 489-494.
[8]	YANG Ju, LIU Qin, LIU Baorui, WEI Jia. Gastric cancer-associated cancer-testis antigen screening and immune infiltration analysis [J]. Journal of Practical Oncology, 2022, 36(6): 495-501.
[9]	GONG Ruining, REN He. Research progress and prospect of immunotherapy for pancreatic ductal adenocarcinoma [J]. Journal of Practical Oncology, 2022, 36(6): 502-506.
[10]	CAO Wenjie, WEI Yuan, KUANG Dongming. Tumor infiltrating B cells and immunotherapies [J]. Journal of Practical Oncology, 2022, 36(6): 507-512.
[11]	ZHANG Yue, WANG Yue, WEI Jia. The value of SHP2 as an anti-tumor therapeutic target and its application in tumor immunotherapy [J]. Journal of Practical Oncology, 2022, 36(6): 513-519.
[12]	CHENG Siyuan, HAN Zihan, GUO Xiaohuan, SHEN Lin, PENG Zhi. Research progress on the relationship between gut microbiota and therapeutic efficacy, and adverse reactions [J]. Journal of Practical Oncology, 2022, 36(6): 520-525.
[13]	LI Xiong, JIANG Wenkai, LANG Zekun, RUI Shaozhen. Research progress on the relationship between tumor-associated neutrophils and pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(5): 458-462.
[14]	TONG Manlin, SHANG Ruru, LIU Xiaohong. Research progress in PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma multiforme [J]. Journal of Practical Oncology, 2022, 36(3): 278-282.
[15]	WU Fangfang, ZHENG Tongsen. Research status and prospect of adjuvant therapy for biliary tract malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 156-161.

Research progress on disease characteristics and immune-related treatment of well-differentiated/dedifferentiated liposarcoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments